Armor Investment Advisors LLC reduced its position in Bristol-Myers Squibb Company (NYSE:BMY) by 5.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,573 shares of the biopharmaceutical company’s stock after selling 752 shares during the period. Armor Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in BMY. Guyasuta Investment Advisors Inc. lifted its position in Bristol-Myers Squibb by 34.5% during the second quarter. Guyasuta Investment Advisors Inc. now owns 36,109 shares of the biopharmaceutical company’s stock valued at $2,012,000 after purchasing an additional 9,265 shares in the last quarter. Tradition Capital Management LLC lifted its position in Bristol-Myers Squibb by 6.2% during the second quarter. Tradition Capital Management LLC now owns 47,361 shares of the biopharmaceutical company’s stock valued at $2,639,000 after purchasing an additional 2,780 shares in the last quarter. Meiji Yasuda Life Insurance Co lifted its position in Bristol-Myers Squibb by 3.5% during the second quarter. Meiji Yasuda Life Insurance Co now owns 43,015 shares of the biopharmaceutical company’s stock valued at $2,397,000 after purchasing an additional 1,470 shares in the last quarter. Baltimore Capital Management Inc. lifted its position in Bristol-Myers Squibb by 2.6% during the second quarter. Baltimore Capital Management Inc. now owns 24,350 shares of the biopharmaceutical company’s stock valued at $1,357,000 after purchasing an additional 610 shares in the last quarter. Finally, Leisure Capital Management lifted its position in Bristol-Myers Squibb by 6.0% during the second quarter. Leisure Capital Management now owns 3,936 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 223 shares in the last quarter. Hedge funds and other institutional investors own 68.97% of the company’s stock.

Several research firms recently weighed in on BMY. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Wednesday, August 16th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Leerink Swann lowered their target price on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a research report on Friday, July 28th. Cowen Inc reiterated a “hold” rating and set a $65.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $64.93.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.23% of the company’s stock.

Shares of Bristol-Myers Squibb Company (BMY) opened at $61.14 on Friday. Bristol-Myers Squibb Company has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The stock has a market capitalization of $100,067.84, a PE ratio of 20.66, a PEG ratio of 2.41 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the firm posted $0.77 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. research analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 61.42%.

ILLEGAL ACTIVITY WARNING: “Armor Investment Advisors LLC Reduces Stake in Bristol-Myers Squibb Company (BMY)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/armor-investment-advisors-llc-reduces-stake-in-bristol-myers-squibb-company-bmy/1723162.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.